Open Orphan (ORPH)

Open Orphan (ORPH) is a rapidly growing niche CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan was founded in 2017 and is led by an experienced management team.

In June 2019 it completed the takeover of AIM listed Venn Life Sciences Holdings plc and in January 2020 it acquired hVIVO plc.

hVIVO is the world leader in testing vaccines and antivirals using human challenge studies. Conducted from its state-of-the-art East London quarantine clinics with individually isolated rooms and connected to its specialist virology laboratory facility.

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution, enabling Venn to create, plan and execute drug development programmes effectively for our customers.

Open Orphan is also building out a valuable data platform business. hVIVO has built up one of the world’s largest databases of infectious disease progression data and our Open Orphan Health Data platform is being populated with this historical hVIVO data.

In our clinical trials going forward, we are also planning to collect data on volunteer’s via wearables during clinical trials. Therefore, Open Orphan’s data, which may yield valuable digital biomarkers, could be one of the more sought-after datasets by many of the large wearables /smart watch wearables providers around the world.

Open Orphan is led by a management team with deep industry and financial experience, with a track record of delivering shareholder value, supported by a highly experienced Board.

Follow Open Orphan on Twitter @OpenOrphan

Here, Cathal Friel discusses the H1 2021 Interim Results & £5.7m influenza human challenge contract

Open Orphan (ORPH)

Recent Posts